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Does heterogeneity matter in the
estimation of tumour budding and tumour
stroma ratio in colon cancer?
Ann C. Eriksen1,2*, Johnnie B. Andersen3,4, Jan Lindebjerg1,2, René dePont Christensen5, Torben F. Hansen1,2,
Sanne Kjær-Frifeldt2 and Flemming B. Sørensen1,2,3,6
Abstract
Background: Tumour budding (TB) and Tumour Stroma Ratio (TSR) may be rewarding in the treatment stratification
of patients with stage II colon cancer. However, lack of standardization may exclude these parameters from being used
in a clinical setting. The purpose of this methodologic study was to compare stereology with semi-quantitative
estimations of TSR, to investigate the intra-tumoural heterogeneity of TB and TSR, and to assess the intra- and
inter-observer agreement.
Methods: Three paraffin embedded tumour blocks, one of them representing the deepest invasive front, were selected
from each of 43 patients treated for stage II colon cancer. TSR was estimated in H&E sections semi-quantitatively using
conventional microscopy, and stereologically on scanned slides, using the newCAST stereology platform. TB was scored
across 10 high power fields at the invasive front in cytokeratin AE1/AE3 stained sections.
Results: Subjective, semi-quantitative estimates of TSR significantly correlated to the stereological estimates, with the best
correlation found for sections with the deepest invasive tumour penetration (σ = 0.621, p < 0.001). Inter-observer
agreement was moderate to substantial for both TB (Κappa = 0.46–0.73) and TSR (Κappa = 0.70–0.75).
The Intraclass correlation coefficient (ICC) for TSR varied from 0.322 based on stereological hotspot estimation to
0.648 for the semi-quantitative evaluation. For TB, ICC varied from 0.646 based on continuous data to 0.698 based
on categorical data (cut-off: 10 buds). Thus, the intra-tumoural heterogeneity for both TB and the semi-quantitative
estimation of TSR was low.
Conclusion: We recommend using only one tissue section representing the deepest invasive tumour area for estimation
of TSR. For TB we recommend using one tissue section; however due to low representation of high-budding tumours,
results must be considered with caution.
Keywords: Colon cancer, Heterogeneity, Tumour budding, Tumour stroma ratio
Background
Colon cancer (CC) is among the most frequent cancers
in the Western World [1]. Survival is primarily corre-
lated to the extension of the disease at the time of diag-
nosis. However, patients diagnosed with the same stage
of disease often have markedly different outcomes [2].
This is a clinical challenge, especially in stage II disease,
and new biomarkers are requested to select high-risk
patients for adjuvant chemotherapy after intended
curative surgery. In this context, the tumour micro-
environment has been investigated in various settings
and several studies have found Tumour Stroma Ratio
(TSR) and Tumour Budding (TB) to provide prognostic
information.
TSR is an estimate of the proportion of malignant epi-
thelial cells and stroma, evaluated in a hematoxylin and
eosin (H&E) stained tissue section, representing the dee-
pest invasive area of the primary tumour [3]. High TSR
(= stroma-low) is associated with significantly better
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overall survival (OS) and recurrence-free survival (RFS)
compared to low TSR (= stroma-high). Several investiga-
tions have reported intra-tumoural stroma-epithelium
ratio, or tumour stromal percentage, to be an independ-
ent prognostic marker of clinical relevance in CC [3–8].
These studies use different methodologies varying from
simple visual, semi-quantitative estimation based on ei-
ther conventional microscopy [3, 4] or digital pathology
[5] to more objective morphometric methods [6, 8].
These various techniques have, to our knowledge not yet
been compared.
Heterogeneity of TSR has been described in individual
tumours [3, 6]. To compensate for this, Mesker et al. [3]
recommended using the histologic section from the pri-
mary tumour with the highest T stage, as they docu-
mented the tumour slide with the deepest infiltration in
the bowel wall to have the lowest fraction of adenocar-
cinoma cells (i.e., highest stroma fraction). Heterogeneity
of TSR in CC needs to be further investigated from the
methodological point of view for future clinical, diagnos-
tic implementation.
TB may reflect the epithelial mesenchymal transition
(EMT) at the invasive tumour front and thus represent
the cell-biological correlate of the tumour-stroma-
interphase. Tumour buds are defined as single tumour
cells, or clusters of up to 4 tumour cells, in the stroma
at the invasive tumour margin [9]. Several studies have
found TB to be a prognostic marker for both stage II
colorectal cancer (CRC) [10–12] and for CC exclusively
[13–15], and it has recently been incorporated into
guidelines such as The College of American Pathologists
Protocol (www.cap.org/cancerprotocols). Also, the Inter-
national Tumor Budding Consensus Conference Group
[16] strongly recommends TB to be included as a high-
risk factor for stage II CRC, and thus clearly recommends
evaluating TB; however, using H&E or immunohisto-
chemical stained sections was an issue for disagreement
in the group. Most studies use H&E stained sections
[10, 11, 13–15], although cytokeratin-stained tissue sec-
tions may detect three to four times more tumour buds
and has a higher reproducibility [17]. Recent studies
have recommended this immunohistochemical ap-
proach for counting TB [12, 18]. Intra-tumoural hetero-
geneity of TB has only been sparsely touched in the
scientific literature. To compensate for tumour hetero-
geneity, a 10-high-power fields (HPFs) scoring tech-
nique has been proposed [12, 18], but the method only
accounts for heterogeneity within the selected section.
Also, it is well known that CC is architecturally, mo-
lecularly, and biologically heterogeneous [19], and
intra-tumoural heterogeneity may have significant im-
pact on the interpretation of biomarkers [20]. This
challenge has to our knowledge not been investigated
for TB in CC.
The aim of this methodological study was to investi-
gate the heterogeneity of TSR and TB in stage II CC,
and to address the issue of whether the histologic sec-
tion representing the deepest invasive tumour margin is
representative of the whole tumour regarding TSR and
TB. We compare semi-quantitative estimation of TSR by
conventional microscopy with the quantitative gold
standard represented by stereology. Finally, we provide
data on intra- and inter-observer reproducibility.
Methods
Patients and tissue
Archival, formalin fixed, paraffin embedded tumour tis-
sue samples from 43 consecutive patients, operated for
stage II CC at the Department of Surgery, Vejle Hospital,
Denmark in 2002, were retrieved. None of the patients
had received preoperative chemo- or radiotherapy. The
study population consisted of six mucinous adenocarcin-
omas and 37 adenocarcinomas (NOS). Mean age was
72.7 years (range 48–70). According to the 7th edition
of American Joint Committee (AJCC) TNM classifica-
tion, 34 of the tumours were classified as T3 and nine as
T4. The total number of tumour-containing tissue
blocks per patient varied from three to 24 (mean = 5.3).
Histologic sections of 4 μm thickness were cut from all
blocks (N = 229) and stained with H&E. Each tumour
was represented by three sections.
Using a 2.5× or 5× objective the section representing
the deepest invasive front of the tumour was selected.
Two additional sections were selected using a random
number table.
Tumour stroma ratio
We estimated TSR in H&E stained sections by two dif-
ferent approaches: a) subjective, manual (semi-quantita-
tive) by conventional microscopy, and b) stereology
(quantitative), using computer assisted software.
a) Using a 2,5× or 5× objective with field size area
78.5mm2 and 19.6 mm2, respectively, the invasive area
with the highest representation of tumour stroma was
selected. Subsequently, using a 10× objective with field
size area 4.9 mm2 the part of the sample with the high-
est fraction of stroma (hot-spot sampling) was subject-
ively selected. Tumour cells were present at all borders
of the image field (north-east-south-west) as described
by Huijbers et al. [4]. The stroma percentage was esti-
mated per microscopic field and scored into four groups
(1: TSR > 75%, 2: 50% < TSR ≤ 75%, 3: 25% < TSR ≤ 50%,
and 4: TSR ≤ 25%). Whenever a score was difficult to
settle in the selected area, the decision was guided by
the overall impression of the stromal fraction in the
tumour. Areas with necrosis were avoided. In mucinous
tumours, the area with mucin was visually excluded for
the scoring. Major vascular structures and smooth
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muscle tissue were also visually excluded, whereas nerves,
smaller vascular structures and lymphocytic infiltration
were not excluded from the stromal compartment.
b) The stereological analysis was performed to obtain
unbiased, absolute estimates of the TSR, using the com-
puter assisted stereology system newCAST (Visiopharm,
Hoersholm, Denmark). All H&E stained sections were
scanned at 40× magnification by a NanoZoomer XR
scanner (Hamamatsu, Japan). The image format was
NanoZoomer Digital Pathology Image (*.ndpi) with a
resolution of 226 nm/pixel (112,389 dots per inch (DPI),
i.e. 4.4 × 4.4 pixels/μm, corresponding to a final magnifi-
cation of × 1.558). First, at low magnification (2×) we es-
timated TSR in the whole tumour area, which was
manually outlined as the region of interest (ROI), and
superimposed a grid with 5 × 5 points (25 points). We
used systematic random, uniform sampling and a sample
fraction of 100%. A point (i.e. a cross) was counted as
tumour, whenever the upper right corner of a cross hit a
viable tumour cell, and as stroma, whenever the upper
right corner of a cross hit a stromal area. Points hitting
areas of smooth muscle, adenoma, tumour lumen, ne-
crosis, mucin, and large vessels were not counted. Sub-
sequently, the area representing the highest density of
stroma (the hotspot sampling) was investigated at × 10
magnification, using a grid with 4 groups and 6 × 7
points (42 points per group) superimposed on the se-
lected area (Fig. 1), and points hitting tumour cells or
stroma were counted as mentioned above. Tumour
cells were required to be present at all borders of the
image field (north-east-south-west) similar to the semi-
quantitative method. The TSR was afterwards calculated as
TSR ¼
P
PtumourP
Ptumourþstroma
, where P denotes points counted.
Immunohistochemistry
Serial sections were cut from the selected tumour blocks
(N = 129) and mounted on FLEX IHC Microscope Slides
(K8020, Agilent DAKO products, Glostrup, Denmark).
The pretreatment processes were performed using PT Link
(DAKO). Heat-induced epitope retrieval was achieved with
Envision Target Retrieval Solution (DAKO) at pH 9 and
97 °C for 20 min. Staining was performed using a DAKO
Autostainer Link 48 (DAKO). Endogenous peroxidase ac-
tivity was blocked by Envision FLEX Peroxidase-Blocking
Reagent (DAKO). The primary antibody was mouse mono-
clonal cytokeratin AE1/AE3 (code M3515, DAKO) diluted
1:250 with Envision Flex antibody diluent (code S2022
DAKO). Primary antibody was incubated for 30 min. at
room temperature, and for amplification Envision Flex+
Mouse (Linker) (DAKO) was used for 20 min. Bound anti-
bodies were detected by Envision FLEX/HRP (DAKO) and
visualised by Envision FLEX DAB (DAKO) with chromo-
gen diluted in Envision Flex Substrate Buffer (DAKO).
Meyer’s hematoxylin (Merck, Darmstadt, Germany) was
used as counterstain and finally, the histological slides were
cover slipped with Tissue-Tek PERTEX (Histolab Products
AB, Göteborg, Sweden).
Tumour budding
The number of tumour buds were counted along the in-
vasive front using pan-cytokeratin (AE1/AE3) stained
sections. First, the sections were examined at low magni-
fication, and the area of the invasive margin representing
the highest density of TB was subjectively selected (hot-
spot sampling). The number of tumour buds were then
counted in 10 HPFs using 40× objective with field size
Fig. 1 Stereological estimation of tumour stroma ratio. a The area
with the highest stroma density (yellow frame) is subjectively selected at
low magnification (2×). b At higher magnification (10×) a grid of 4 x
(6 × 7) points is superimposed on the selected area. Points hitting either
tumour cells or stroma are counted separately. Tumour cells must to be
present at all borders of the visual field (north-east-south-west)
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area 0.3 mm2 (Fig. 2). The first HPF was placed in the
area with the highest budding density, and sampling of
HPFs with the highest number of tumour buds were
searched in both directions along the invasive tumour
margin. A tumour bud was defined as an isolated, single
adenocarcinoma cell or a small cluster of up to 4
tumour cells as defined by Ueno et al. [9]. Adenocarcin-
oma cells were excluded from the counts if they did not
expose a clearly defined, blue stained nucleus to avoid
counting immunohistochemically stained, brown cyto-
plasmic fragments and artefacts.
Reproducibility of TSR and TB
Intra-observer analysis was performed on all sections for
both TB and the semi-quantitative estimation of TSR
with a four-week washout period as count A1 and A2,
respectively. For inter-observer analysis a subset of 50
randomly selected sections was chosen, and TSR and TB
were estimated by an independent observer as count B.
The stereological, quantitative evaluation of TSR was
not reproduced according to the high reliability of ste-
reological methods.
Statistical analysis
Data were summarized and inspected by standard statis-
tical methods. Inter- and intra-tumoural variability was
assessed by calculation of intra-class correlation coeffi-
cients (ICC) [21], using a mixed-effects model. In this
setting ICC is a ratio of variances and considered as the
percentage of the total variance accounted for by the dif-
ferences among the tumours examined. The ICC will be
high (ICC→ 1) if the majority of the estimator variation
is attributable to inter-tumoral variation, i.e. biological
variation among the patients. In case the majority of
variation is caused by intra-tumoral variation, i.e. hetero-
geneity, the ICC will be low (ICC→ 0).
We used chi2-test to compare the estimates of TSR
obtained by stereology and conventional microscopy.
The correlations were evaluated by Spearman’s correl-
ation coefficients, and the differences were tested using
Wilcoxon signed rank test. The correlations of TB ob-
tained in the deepest invasive section and the two ran-
domly selected sections were evaluated by Pearson’s
correlation coefficient, while Wilcoxon signed rank test
was used to investigate differences in the mean number
of buds between the three sections. Simple and weighted
kappa (K) values were generated to compare intra- and
inter-observer variability [22], and agreement was de-
scribed according to Landis et al. [23] as moderate, sub-
stantial, and almost perfect for Κ values of 0.41–0.60,
0.61–0.80, and 0.81–1, respectively. All tests were two-
sided and P-values less than 0.05 considered significant.
The statistical analysis was performed using the software
STATA version 14.0 (StataCorp, Texas, USA).
Results
Tumour stroma ratio
Comparison of stereological and semi-quantitative
estimates of tumour stroma ratio
Using stereology the mean stromal fraction of all sec-
tions was 0.34 (range: 0.04–0.84) for the whole tumour
area and 0.56 (range: 0.12–0.94) for the hot-spot sam-
pling area. We found the semi-quantitative method to
underestimate TSR compared to stereological estimates
of the hot-spot sampled area (p < 0.001), and there was a
trend towards overestimation of TSR compared to the
stereological estimate within the whole tumour area
(p = 0.291) (Additional file 1: Table S1).
The correlation between the semi-quantitative and
stereological techniques was analyzed for all sections
(N = 129) and for each of the three individual sec-
tions from each tumour, i.e. the section with the deepest
tumour penetration and the two randomly selected sec-
tions A and B (Table 1). Except for random section B, the
correlations were best for the hot-spot sampled areas, es-
pecially when based on the tissue section with the deepest
tumour invasion.
Intra-tumoural heterogeneity of tumour stroma ratio
We found the ICCs obtained by the semi-quantitative
method to be considerably higher than those obtained
by stereology (Table 2). For the stereological estimates,
we calculated ICCs, using both the continuous raw data
and the ordinal data divided into the four groups and
found similar results.
Using the semi-quantitative method, we found a fairly
good correlation between “the deepest invasive section”
Fig. 2 Counting tumour budding in a high power field (HPF). The
number of tumour buds (TB) was counted along the invasive front
on cytokeratin AE1/AE3 stained sections in 10 HPF. A tumour bud
was defined as an isolated single tumour cell or a cluster of up to
four tumour cells (arrows). Adenocarcinoma cells without a clear
nucleus and cytoplasmatic fragments (arrowheads) were not
counted. Magnification 40×
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and the two randomly chosen sections A and B, re-
spectively (Additional file 1: Table S2). Based on stereo-
logical estimates for the whole tumour area, the
correlations were decreasing and they decreased further
when using stereological estimates based on sampling
in the hot-spot area.
Intra- and inter-observer reproducibility of tumour
stroma ratio
The intra-observer agreement for the semi-quantitative
estimation of TSR was overall substantial (Kappa range
0.65–0.77) and improved to almost perfect (Kappa range
0.78–0.83), when categorizing the four tiered TSR-data
into high (TSR > 50%) or low (TSR ≤ 50%). Also, the
inter-observer agreement increased, when categorized
into two groups (Kappa range 0.70–0.75) (Table 3).
Budding
Estimates of tumour budding
Including all sections we found a mean of 3.55 buds
(range 0–32) per HPF, and the 50% percentile (median)
was 2.7 buds per HPF. Using 10 buds per HPF as cut-off,
we defined high-budding as an average of ≥10 buds
across 10 HPFs, as proposed by Karamitopoulou et al.
[18]. We found that 122 (94.6%) of the histological slides
were classified as low-budding and seven (5.4%) as high-
budding.
The mean number of buds per HPF was 3.5 for the
sections representing the deepest invasive tumour mar-
gin and 3.8 and 3.3 for the randomly selected sections A
and B, respectively. The Pearson correlation coefficients
for the correlation between the deepest invasive tumour
section and the random sections A or B ranged from
0.674 for the correlation between the former and ran-
dom section A (count A1) to 0.812 for the correlation
with random section B (count A2) (p < 0.001).
Heterogeneity of tumour budding
The magnitude of ICCs for TB was similar to that ob-
tained for TSR (Table 4) and with similar results, when
analyzed on the mean or the data converted into high-
or low-budding. According to the calculated values of
ICC, the majority of the variation is attributable to bio-
logical differences among the tumours. In count A1 the
ICC of 0.646 means that 35.4% of the total variance is
due to variation within the single tumour (heterogeneity
and measurement noise). Thus, the intra-tumoural vari-
ation is considerably lower than the inter-tumoral variation.
Intra- and inter-observer reproducibility of tumour budding
Overall, the intra-observer agreement was in a clinically
useful range varying from moderate to substantial
(Table 5). The kappa values increased when only consider-
ing the deepest invasive tumour section (Kappa = 0.79).
The inter-observer agreement was moderate to substantial
(Kappa range 0.46–0.73).
Discussion
In this methodological study we investigated the hetero-
geneity of TSR and TB in 43 consecutive stage II adeno-
carcinomas of the colon and found that the intra-
tumoural variation of both TSR and TB was considerably
lower than the biological variation. We also compared
semi-quantitative estimates of TSR based on conven-
tional microscopy with unbiased, stereological estimates
and found a significant correlation between semi-
quantitative estimates and stereological estimates in hot-
spot sampled areas, especially when only considering the
deepest invasive tumour section.
Table 1 Correlation between estimates of tumuor stroma ratio obtained semi-quantitatively and by stereology
Spearman’s correlation
All sections
(n = 129)
Spearman’s correlation
Deepest section
(n = 43)
Spearman’s correlation
Random section A
(n = 43)
Spearman’s correlation
Random section B
(n = 43)
Stereology (whole tumour area) and
semi-quantitative method
0.424, p < 0.001 0.461, p < 0.002 0.230, p = 0.139 0.551, p < 0.001
Stereology (hot-spot sampled area) and
semi-quantitative method
0.579, p < 0.001 0.621, p < 0.001 0.598, p < 0.001 0.501, p < 0.001
Semi-quantitative tumour stroma ratio was estimated by conventional microscopy. The stereological estimation was done either in the whole tumour area of the
section or in the hot-spot sampled area. Correlation for all sections (n = 129) and for individual tumour sections (n = 43)
Table 2 Intra-class correlation coefficients (ICC) for estimates of
tumour stroma ratio
ICC 95% CI
Semi quantitative method A1 0.648 (0.533–0.762)
Semi quantitative method A2 0.611 (0.488–0.733)
Stereology (whole tumour area;
continuous data)
0.592 (0.465–0.718)
Stereology (hot-spot sampled area;
continuous data)
0.393 (0.236–0.550)
Stereology (whole tumour area;
data categorized in 4 groups)
0.451 (0.301–0.601)
Stereology (hot-spot sampled area;
data categorized in 4 groups)
0.322 (0.158–0.485)
Tumour stroma ratio (TSR) was estimated semi-quantitatively by
conventional microscopy
Stereological TSR was estimated both in the whole available tumour area of
the section and in the hot-spot sampled area
Abbreviations: CI confidence interval
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Heterogeneity of tumour stroma ratio and tumour
budding
We investigated the heterogeneity using three sections,
well aware that this only represents a minor part of the
whole tumour. Because of the retrospective design, it
was impossible to overcome sampling bias, as the inves-
tigated tissue had already been sampled and prepared
for diagnostic purposes. ICCs estimated by conventional
microscopy for both TB and TSR are comparable. The
similarity in intratumoral heterogeneity may reflect TB
as the cell-biological correlate of the tumour stroma
interphase.
We found ICCs for the stereological estimates of TSR
to be considerably lower than the ICCs calculated for
the semi-quantitative estimates. Moreover, the stereo-
logical estimates of TSR in the hot-spot sampled areas
revealed a considerably lower ICC than those obtained
from the whole tumour area. This reflects the differ-
ences in technical approach and may be explained by
the higher degree of detail and precision afforded by
stereology. The level of detail is highest in the stereo-
logical hot-spot sampled estimation of TSR, and as ex-
pected this results in the highest level of intratumoral
heterogeneity.
Comparison of stereological and semi-quantitative
estimates of tumour stroma ratio
Stereology is considered the gold standard for obtain-
ing quantitative, histopathological data, but only one
other study has measured the relative proportion of
tumour cells using virtual slides and point counting
[6]. Comparison, however, was not made with any
semi-quantitative method.
We found significant correlations for TSR obtained by
stereology in the hot-spot sampled areas and by the
semi-quantitative technique. Nevertheless, there were
discrepancies. Part of the explanation might be the use
of different study fields for the stereological hot-spot es-
timation and the semi-quantitative estimation, as these
were not aligned but chosen subjectively for each
method, guided by the highest stromal fraction. The
‘borderline’ cases were characterized by difficulty in dis-
tinguishing stroma and smooth muscle tissue. Morpho-
logically, these two types of tissue can be distinguished
by careful inspection of the cell nuclei. The smooth
muscle cells have nuclei with rounded ends (cigar-shaped),
while fibroblasts have more spindle shaped nuclei. Also,
the smooth muscle fibres are often more eosinophilic in
H&E stained sections than the collagenous, fibroblas-
tic stroma. For some troublesome cases one may use
Masson’s Trichrome, which stains smooth muscle fi-
bres red and collagen fibres blue. Another option is
immunohistochemical stain for desmin, which identi-
fies smooth muscle fibres (Fig. 3). Both methods af-
ford an easy distinguishing of fibrous stroma versus
smooth muscle tissue.
Distinguishing fibrous stroma from smooth muscle tis-
sue was problematic for both the stereological and the
semi-quantitative approach. However, when in doubt
using the semi-quantitative technique we had the possi-
bility to find and compare the area of interest with the
area of tunica muscularis, and the final decision was
made “eye-balling” the overall representation of stroma
in the whole tumour area. This was not an option for
Table 3 Intra-and inter-observer kappa values for semi-
quantitative estimates of tumour stroma ratio
N Kappa values
(TSR: 4-groups)
Kappa values
(TSR: High/Low)
Weighted kappa
(TSR: 4 groups)
TSR-A1 & TSR-A2 129 0.68, p < 0.001 0.83, p < 0.001 0.77, p < 0.001
TSR-A1 & TSR-A2 43 0.65, p < 0.001 0.78, p < 0.001 0.75, p < 0.001
TSR-A1 & TSR-B 50 0.45, p < 0.001 0.75, p < 0.001 0.64, p < 0.001
TSR-A2 & TSR-B 50 0.47, p < 0.001 0.70, p < 0.001 0.67, p < 0.001
Tumour stroma ratio was estimated semi-quantitatively by conventional
microscopy. Intra-observer kappa values were calculated for all sections
(n = 129) and the deepest invasive tumour section (n = 43), and inter-observer
kappa values were calculated for 50 randomly selected sections. Kappa values
were calculated for data expressed in four groups; TSR-4-groups (1: TSR > 75%,
2: 50% < TSR ≤ 75%, 3: 25% < TSR ≤ 50%, 4: TSR ≤ 25%) and data expressed in
two groups; TSR high/low (high TSR = stroma ≤50% and low TSR:
stroma > 50%)
Abbreviations: TSR tumour stroma ratio; A1 First count by observer A; A2
second count by observer A; B count by observer B
Table 4 Intra-class correlation coefficient (ICC) for tumour
budding
ICC 95% CI
TB-A1 0.646 0.529–0.763
TB-A2 0.669 0.556–0.778
TB-A1 (cut-off 10) 0.650 0.536–0.764
TB-A2 (cut-off 10) 0.698 0.596–0.800
ICC is calculated for continuous data and for data divided into categories as
low-budding (< 10 buds) and high-budding (≥ 10 buds) (n = 129)
Abbreviations: CI confidence interval; TB tumour budding; A1 First count by
observer A; A2 second count by observer A
Table 5 Intra- and inter-observer agreement data for scoring of
tumour budding
N Kappa values
(Cut-off ≥10 buds)
Weighted kappa values
(Continuous TB-scale)
TB-A1 & TB-A2 129 0.60, p < 0.001 0.70, p < 0.001
TB-A1 & TB-A2 43 0.79, p < 0.001 0.79, p < 0.001
TB-A1 & TB-B 50 0.46, p < 0.001 0.54, p < 0.001
TB-A2 & TB-B 50 0.73, p < 0.001 0.59, p < 0.001
Kappa was calculated for continuous data and for data divided into categories
as low-budding and high-budding with a cut-off for high-budding of ≥10
buds. Intra-observer kappa was calculated for all sections (n = 129) and for the
deepest invasive tumour section (n = 43). Inter-observer kappa was calculated
for 50 randomly selected cases
Abbreviations: TB tumour budding; A1 First count by observer A; A2 second
count by observer A; B count by observer B
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the stereological approach, and some variation was ex-
pected due to the subjectivity in deciding on fibrous stroma
or smooth muscle. We have not investigated intra- and
inter-observer variation for the stereological estimation, but
studies using a similar approach report excellent inter-
observer agreement with kappa values of 0.97 [6] and 0.986
[8]. Overall, stereological estimations have a high reprodu-
cibility due to the strict sampling and counting rules.
For the semi-quantitative method we found a moderate
to substantial intra- and inter-observer agreement, which
was optimized by using a dichotomized categorization.
This is in accordance with previous studies using the same
method, but results vary. In a recent study, TSR was eval-
uated using both a “global” method, estimating TSR in the
whole available tumour area, and a “focal” method evalu-
ating TSR in one single field (× 10 magnification) in the
deepest invasive region of the tumour. The authors found
method-dependent kappa values for intra-observer agree-
ment of 0.45 (focal) and 0.84 (global), and the inter-
observer kappa values were reported in the range 0.13–0.53
(focal) and 0.48–1.00 (global) [7]. The finding of the best
TSR reproducibility being afforded by the “global” method
contradicts earlier studies. A study using the “focal” method
yielded an inter-observer kappa value of 0.89 [4], while
studies using the “global” method reported kappa values be-
tween 0.60 and 0.70 [3, 24]. High inter-observer agreement
on TSR has also been found in esophageal cancer based on
the “focal” technical approach [25].
Estimation of TSR in mucinous tumours is debated.
We investigated the impact of the mucinous component
in the six mucinous adenocarcinomas included in our
study by performing a sensitivity analysis excluding the
sections of mucinous CC (n = 18). This resulted in al-
most unchanged correlation coefficients for correlations
between the subjective, semi-quantitative estimates of TSR
and the stereological estimates; 0.431 for whole section and
0.571 for hotspot area (p < 0.0001; data not shown).
Time consumption is a considerable disadvantage of ste-
reological estimation of TSR. West et al [6] spent approxi-
mately 20 min per case and we spent on average 10 min
per section. Thus, for routine use the stereological approach
is considered too time consuming, whereas the semi-
quantitative technique can be carried out in less than one
minute. With optimal tissue stains and strict scoring cri-
teria (Table 6), this method is reproducible and suited for
the clinical setting.
Table 6 Scoring criteria for semi-quantitative estimation of
tumour stroma ratio with a list of structures to be included or
excluded in the estimation
Structure Inclusion Handling of problem
Necrosis No Select another area or
another section if possible
Mucin No Select another area
Major vascular structures No Visual exclusion
Minor vascular structures Yes –
Smooth muscle tissue No Masson’s trichrome or
desmin stains
Nerves Yes –
Lymphocytes Yes Dense infiltrates with
neutrophil granulocytes
are excluded as necrosis
Adenoma No Visual exclusion
Fig. 3 How to distinguish fibrous tumour stroma from smooth
muscle tissue. a In the H&E stained section it is challenging to
distinguish between fibrous stroma and smooth muscle tissue.
b Immunohistochemical stain for desmin highlights the smooth
muscle tissue. c Masson trichrome highlights the collagen fibres in
the fibrous stroma (blue) and the smooth muscle tissue (purple-red).
Magnification 10×
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Estimates of tumour budding
Estimates of TB were obtained by the 10 HPFs method
on pan-cytokeratin (AE1/AE3) stained sections as rec-
ommended in a recent review [26]. We found a consid-
erable lower mean number of buds, and likewise lower
proportion of high-budding tumours compared to other
studies estimating TB on pan-cytokeratin stained sec-
tions [12, 27]; however the published studies are not
comparable regarding both study population and tech-
niques used. Horic M et al. [12] reported a higher me-
dian bud count of 8.05, but this study includes both
colon and rectum cancer. Koelzer V H et al. [27] found
a mean of 7.11 buds per HPF and 30.7% to be high-
budding; however their cohorte also included upper rec-
tal tumours. It is not described in the literature, whether
the occurrence of TB in rectum cancers is comparable
to TB in CC. Rectum tumours may represent a group
with higher occurrence of TB than colon tumours, and
in that case the two types of tumours must be consid-
ered separately according to TB.
Koelzer V H et al. [27] selected the section with the
highest number of buds presented on H&E for IHC stain
and evaluation of TB, while we used the deepest invasive
section and further two randomly selected sections. In
addition we only counted TB cells with a clearly identifi-
able nucleus to avoid cytoplasmic fragments etc., and
our TB count might be lower due to this counting rule.
Interestingly, we found inter-observer agreement similar
to Koelzer V H et al., and thus the difference may exist
in between centers. In regard to future studies using
IHC, it is important to standardize this method of
counting.
Overall we found acceptable intra- and inter-observer
agreement, which is in accordance with earlier studies
using the same method [17, 18]. However, a multicenter
study found considerably lower reproducibility [28], but
an explanation of this could be the selection of cases
with only doubtful or controversial TB. We did not in-
vestigate TB using H&E, and thus we only discuss diffi-
culties related to the use of IHC. We experienced
differences in the definition of a clear nuclear stain and
whether to count groups of tumour cells with TB ap-
pearance lying in between more solid areas, as these
may represent cutting artefact of the cohesive 3D adeno-
carcinoma structure rather than real tumour buds. A
disadvantage of the use of cytokeratin AE1/AE3 is the
broad reactivity with staining of cell types other than the
malignant adenocarcinoma cells. For instance, we expe-
rienced positive AE1/AE3 stain of mesothelial hyperpla-
sia, which can be found in all serous membranes, and in
some cases it was difficult to distinguish such cells from
budding cells. A stain for cytokeratin 20 (CK 20) may
distinguish budding cells from mesothelial hyperplasia,
as the latter is negative for this particular cytokeratin.
Unfortunately, we have experienced CK20 to be negative
in approximately 10% of adenocarcinomas of the colon.
We also detected AE1/AE3 positive staining of endo-
thelial cells of vascular neoangiogenesis, which could be
difficult to distinguish from TB cells. However, strict cri-
teria demanding a discernible nucleus in the tumour cell
or a lumen in a vessel were helpful in most cases.
A number of other structures can have a budding-like
appearance: fragmentation of tumour glands induced by
abundant inflammatory infiltrate; retraction artifacts
around fragmented tumour glands; fragments of tumour
tissue surrounded by abundant mucinous extracellular
matrix. Cytoplasmic fragments were also disturbing ele-
ments, but the strict rule of a visible tumour cell nu-
cleus proved useful, as reported earlier in a multicenter
study [17].
Conclusion
This study of adenocarcinomas of the colon documents
visual, subjective, semi-quantitative estimates of TSR to
be correlated to stereological estimates of TSR with the
best correlation afforded using the histological section
with the deepest invasive tumour penetration. For both
TSR and TB we found moderate to substantial inter-
observer agreement, minor intra-tumoral heterogeneity,
and high correlation among sections from the same
tumour. For future studies of TSR we recommend the
easy, cost efficient, and fast semi-quantitative technique
and the use of one tissue section representing the dee-
pest invasive tumour area of the adenocarcinoma. Re-
garding TB, we recommend using one tissue section.
Considering the low proportion of high-budding tu-
mours, further methodological studies are needed for
evaluation of TB heterogeneity in rectal adenocarcinoma
and CC in more advanced clinical stage of disease.
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